![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sage Therapeutics Inc | NASDAQ:SAGE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.245 | 3.12% | 8.105 | 8.10 | 8.11 | 8.20 | 7.79 | 7.94 | 251,925 | 19:07:11 |
Effort embodies Sage’s long-term commitment to investing in People, Patients, Planet and Community
Sage Therapeutics (Nasdaq: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced the launch of SageCitizen – a corporate social impact effort that activates and amplifies Sage’s long-term commitment to People, Patients, Planet and Community.
“At the core of our work at Sage is our mission to transform the lives of people with brain health disorders. We see the potential positive impact we can have on individuals, families and society not just with the novel treatments that we are developing, but with our engagement in the communities where we live and work,” said Barry Greene, Chief Executive Officer at Sage Therapeutics. “In the context of the current brain health pandemic, the launch of SageCitizen solidifies our deep, long-term relationships with community partners in a strategic and holistic way that aligns with our goal of making a meaningful and sustained contribution to people and society.”
SageCitizen launched with more than 200 Sage employee volunteers participating in a week of service comprised of virtual and in-person activities, including:
SageCitizen formalizes Sage’s social impact efforts, further strengthening the social impact of the philanthropic and community activities Sage and its employees have been involved in since 2014. SageCitizen is organized around four pillars:
Through SageCitizen, Sage seeks to deepen relationships with its partners by developing more long-term engagement opportunities that are intended to increase impact on the well-being of Sage’s people, patients, planet, and communities where they work and live.
“Putting people first is part of everything we do at Sage – from how we engage and treat patients and their families, to the respect and compassion we have for each other, our community and our planet,” said Erin Lanciani, Chief People & Experience Officer, Sage Therapeutics. “We are thrilled to formalize these efforts as we launch SageCitizen.”
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner. For more information, please visit www.sagerx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211001005134/en/
Investor Contact Helen Rubinstein 315-382-3979 helen.rubinstein@sagerx.com
Media Contact Maureen L. Suda 617-949-4289 maureen.suda@sagerx.com
1 Year Sage Therapeutics Chart |
1 Month Sage Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions